10-Q: MannKind Reports Q2 Profit, Secures $500M Blackstone Loan

MannKind Corporation achieved net income in the second quarter of 2025, driven by strong royalty revenue from Tyvaso DPI and growth in Afrezza sales, while significantly bolstering its liquidity with a new $500 million credit facility from Blackstone.

Summary

• Net income for the second quarter of 2025 was $0.7 million, a significant improvement from a net loss of $2.0 million in the same period of 2024.
• Net income for the six months ended June 30, 2025, increased to $13.8 million, up from $8.6 million in the prior year period.
• Total revenues grew by 6% to $76.5 million in Q2 2025 and by 12% to $154.9 million for the first half of 2025.
• Royalty revenue from United Therapeutics' Tyvaso DPI sales surged by 22% to $31.2 million in Q2 2025 and by 27% to $61.2 million for H1 2025.
• Afrezza net revenue increased by 13% to $18.3 million in Q2 2025 and by 8% to $33.2 million in H1 2025, primarily due to increased price and higher demand.
• V-Go net revenue decreased by 8% to $4.1 million in Q2 2025 and by 7% to $8.2 million in H1 2025, mainly due to lower demand, partially offset by increased price and improved gross-to-net adjustments.
• Collaboration and services revenue decreased by 12% in Q2 2025 to $22.8 million but increased by 3% in H1 2025 to $52.2 million, influenced by the Amphastar co-promote agreement.
• Total expenses rose by 28% to $71.2 million in Q2 2025 and by 21% to $127.3 million in H1 2025, driven by increased research and development and selling, general and administrative costs.
• Research and development expenses increased by 16% in Q2 2025 to $13.7 million and by 13% in H1 2025 to $24.7 million, primarily due to ongoing clinical studies (ICoN-1 for MNKD-101, clinical production scale-up for MNKD-201) and personnel costs from the Pulmatrix transaction.
• Selling, general and administrative expenses increased by 31% in Q2 2025 to $31.6 million and by 22% in H1 2025 to $56.6 million, mainly due to higher headcount, personnel-related costs, and Afrezza promotional activities.
• A foreign currency transaction loss of $5.4 million was recorded in Q2 2025, compared to a gain of $0.5 million in Q2 2024, due to U.S. dollar to Euro exchange rate fluctuations related to the Insulin Supply Agreement.
• Interest expense significantly decreased due to principal debt reductions in 2024, including the exchange of senior convertible notes and repayment of MidCap credit facility and Mann Group convertible note.
• Cash and cash equivalents increased to $57.0 million as of June 30, 2025, from $46.3 million at December 31, 2024.
• Total liquidity (cash, cash equivalents, and investments) stood at $201.2 million as of June 30, 2025.
• The accumulated deficit decreased to $3.188 billion as of June 30, 2025, from $3.202 billion at December 31, 2024.
• Total stockholders' deficit improved to -$55.0 million as of June 30, 2025, from -$78.8 million at December 31, 2024.

Sentiment

Score: 8

Explanation: The company demonstrated a return to net income for the quarter and half-year, driven by strong royalty revenue from Tyvaso DPI and growth in Afrezza sales. The new $500 million Blackstone credit facility significantly enhances liquidity and financial flexibility, de-risking the near-term outlook. While V-Go sales declined and operating expenses increased, the overall financial health and strategic progress in the pipeline are positive, indicating a strong improving trend.

Positives

• Achieved net income of $0.7 million in Q2 2025 and $13.8 million in H1 2025, a significant turnaround from a net loss in the prior year quarter.
• Experienced strong growth in royalty revenue from Tyvaso DPI, increasing by 22% in Q2 2025 and 27% in H1 2025, reflecting increased net sales by United Therapeutics.
• Afrezza net revenue grew by 13% in Q2 2025 and 8% in H1 2025, driven by increased price and higher demand, with an improved gross-to-net adjustment.
• Successfully reduced overall interest expense due to strategic debt reductions in 2024, including the exchange of senior convertible notes and repayment of other credit facilities.
• Increased cash and cash equivalents to $57.0 million and maintained total liquidity at $201.2 million as of June 30, 2025.
• Secured a new senior secured term loan agreement with Blackstone for up to $500 million, with an initial funding of $75 million, significantly enhancing financial flexibility and liquidity.
• Progressed pipeline assets with continued patient enrollment in the Phase 3 ICoN-1 clinical study for MNKD-101 and planning for a global Phase 2 trial for MNKD-201 with site activation expected by year-end 2025.
• Reduced the accumulated deficit and total stockholders' deficit, indicating an improvement in overall financial health.

Negatives

• V-Go net revenue decreased by 8% in Q2 2025 and 7% in H1 2025, primarily due to lower demand.
• Collaboration and services revenue decreased by 12% in Q2 2025, mainly due to a decline in revenue from product sold to United Therapeutics and deferred revenue recognition.
• Operating income decreased by 68% in Q2 2025 and 17% in H1 2025, primarily due to a substantial increase in operating expenses.
• Research and development expenses increased by 16% in Q2 2025 and 13% in H1 2025, reflecting higher costs for clinical studies and personnel.
• Selling, general and administrative expenses increased significantly by 31% in Q2 2025 and 22% in H1 2025, driven by higher headcount and promotional costs.
• Incurred a substantial foreign currency transaction loss of $5.4 million in Q2 2025, a significant swing from a gain in the prior year, due to Euro exchange rate fluctuations.
• Net cash provided by operating activities decreased to $2.6 million in H1 2025 from $10.5 million in H1 2024.
• Interest income decreased by 42% in Q2 2025 and 43% in H1 2025 due to a lower average balance on the securities portfolio and lower yields.

Risks

• Commercial success of products may be limited due to factors like market acceptance, competition, and payer coverage/reimbursement.
• Manufacturing risks, including difficulties in production, capacity utilization, yields, and compliance with regulations, could adversely affect ability to manufacture products and Tyvaso DPI, potentially reducing gross margin and profitability.
• Reliance on a limited number of suppliers for critical materials (e.g., Amphastar for insulin, China manufacturers for V-Go) exposes the company to risks of supply disruption, pricing issues, and quality control.
• International trade policies, including tariffs and trade barriers, may increase costs for raw materials and components, adversely affecting financial performance.
• If third-party payers do not provide adequate coverage and reimbursement for approved products, sales could be adversely affected.
• The company may need to raise additional capital to fund operations, and it may be difficult to do so on favorable terms or at all, potentially leading to delays or curtailment of programs.
• Compromised data or information technology systems, or those of third parties, could lead to regulatory investigations, litigation, fines, business disruptions, and reputational harm.
• Operating results are expected to fluctuate, making future performance difficult to predict.
• The company may incur future losses and may not generate sufficient positive cash flow from operations, impacting working capital and ability to service indebtedness.
• Continued testing of product candidates may not yield successful results, and even if successful, commercialization may not occur.
• Failure to achieve projected development goals in expected timeframes could harm business and financial results.
• Long-term safety and efficacy of approved products may differ from clinical studies, potentially leading to reduced sales, reputational harm, or regulatory actions.
• Products and product candidates may be rendered obsolete by rapid technological change and new competitive products.
• Future internal restructuring activities could result in business disruptions or materially harm results of operations.
• Changes in funding or staffing for regulatory agencies (FDA, SEC) could hinder their ability to perform normal functions, negatively impacting the business.
• The new Blackstone Credit Facility contains restrictive covenants that may limit operating flexibility, and a default could materially and adversely affect the financial position.
• Failure to comply with regulatory requirements at any stage (before or after marketing approval) could result in fines, product removal, or criminal prosecution.
• Non-compliance with federal and state healthcare laws, including fraud and abuse and health information laws, could lead to substantial penalties.
• Stringent and evolving data privacy and security laws pose risks of regulatory investigations, litigation, fines, and business disruptions.
• The stock price is volatile and future sales of common stock could depress the price.
• Unstable market, economic, and geopolitical conditions (e.g., inflation, conflicts) may have serious adverse consequences on business and stock price.
• Operations are concentrated in specific facilities (Danbury, CT for Afrezza/Tyvaso DPI; Southern China for V-Go) and could be interrupted by natural disasters or catastrophic events.
• Adverse developments affecting the financial services industry could impact current and projected business operations and financial condition.
• Inability to protect proprietary intellectual property rights could hinder effective competition or profitability.
• Conflicts with the proprietary rights of others could lead to substantial litigation costs and potential inability to commercialize products.
• May not obtain trademark registrations for potential trade names, limiting competitive advantage.
• Healthcare legislation and government initiatives (e.g., IRA, OBBBA) may make it more difficult to generate revenues due to pricing and reimbursement pressures.
• Failure to comply with Medicaid Drug Rebate Program or other governmental pricing programs could lead to additional reimbursement requirements, fines, and sanctions.
• Environmental, social, and corporate governance (ESG) matters or reporting could negatively impact the business or stock price.
• The portfolio of investment securities may require registration with the SEC as an investment company, imposing significant restrictions and administrative costs.

Future Outlook

The company expects enrollment for its global Phase 3 registrational study of inhaled clofazimine (MNKD-101) to continue into 2026. A global Phase 2 trial for nintedanib dry-powder formulation (MNKD-201) is planned, with clinical trial site activation anticipated by year-end 2025. Management believes that current revenue streams from Afrezza, V-Go, and Tyvaso DPI, combined with the recently secured Blackstone credit facility, will provide sufficient liquidity to meet operational needs for at least the next 12 months and in the longer term. Substantial expenditures are expected to continue for manufacturing, marketing, and product candidate development. The company may also seek to retire or purchase outstanding senior convertible notes.

Management Comments

• Our future success is dependent on our, and our current and future collaboration partners, ability to effectively commercialize approved products.
• Our future success is also dependent on our pipeline of new products.
• There is a high rate of failure inherent in the R&D process for new drugs.
• We expect enrollment of subjects into this study [ICoN-1] to continue into 2026.
• We are currently planning a global Phase 2 trial [for MNKD-201] and we expect clinical trial site activation by year end 2025.
• In combination with our cash, cash equivalents and investments on hand, we believe that these sources of revenue, as well as the potential financing sources currently available to us, will allow us to meet our liquidity needs over the next 12 months and in the longer term.

Industry Context

MannKind operates in the biopharmaceutical industry, specializing in endocrine and orphan lung diseases, leveraging its Technosphere dry-powder formulations and Dreamboat inhalation devices. The company commercializes Afrezza for diabetes and V-Go for insulin delivery, and partners with United Therapeutics for Tyvaso DPI in pulmonary hypertension. Its pipeline includes treatments for severe chronic pulmonary infections (MNKD-101) and idiopathic pulmonary fibrosis (MNKD-201). The industry is characterized by intense competition for talent, rapid technological advancements, and a stringent regulatory environment. Recent healthcare legislation, such as the Inflation Reduction Act and the One Big Beautiful Bill Act, continues to impact drug pricing and reimbursement, potentially affecting revenue opportunities. Global supply chain disruptions and geopolitical tensions also pose ongoing risks to operational costs and overall business stability.

Comparison to Industry Standards

• The company's insurance coverage is maintained with financially sound and reputable companies, of types and amounts customarily insured against by persons of comparable size engaged in the same or similar business.
• The terms of the Permitted Convertible Bond Indebtedness are consistent with customary market terms for public convertible bonds.
• The company acknowledges that it has limited resources compared to some of its competitors in the biopharmaceutical and device industries, which have more experience and resources for commercialization.
• The company faces competition from universities and other non-profit research organizations that are increasingly active in seeking patent and licensing revenues.
• The company's policies and measures for data privacy and security are commercially reasonable and customary in the pharmaceutical industry.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to legal proceedings and claims that arise in the ordinary course of its business, but does not anticipate the final disposition of any matters will have a material adverse effect on its results of operations, financial position, or cash flows.

Related Party Transactions

• The company has an Insulin Supply Agreement with Amphastar Pharmaceuticals, Inc. for the manufacture and supply of recombinant human insulin for Afrezza, which was amended in December 2023 to extend the term and restructure annual purchase commitments.
• The company previously had a convertible note arrangement with The Mann Group, which was discharged and terminated in April 2024.
• The company has a Milestone Rights Purchase Agreement with Deerfield Private Design Fund II, L.P. and Horizon Sant FLML SRL (now held by Milestone Purchasers), entitling them to payments upon specified strategic and sales milestones, with $45.0 million remaining payable as of June 30, 2025.

Stakeholder Impact

• Shareholders: Potential for increased share value due to improved financial performance, pipeline progress, and enhanced liquidity, but also face potential dilution from future equity raises and stock price volatility.
• Employees: Increased headcount and personnel-related costs, indicating growth, but also a notable executive separation.
• Customers (Patients/Healthcare Providers): Continued access to commercialized products (Afrezza, V-Go, Tyvaso DPI) and potential for new therapeutic options from the pipeline.
• Suppliers: Continued reliance on key suppliers, particularly for insulin and V-Go manufacturing, with exposure to international trade policies and tariffs.
• Creditors: Strengthened ability to meet debt obligations due to improved financial results and the substantial new Blackstone Credit Facility, reducing credit risk.

Next Steps

• Continue patient enrollment in the global Phase 3 registrational study of inhaled clofazimine (MNKD-101) into 2026.
• Plan for a global Phase 2 trial for nintedanib dry-powder formulation (MNKD-201), with clinical trial site activation expected by year-end 2025.
• Manage substantial ongoing expenditures for manufacturing operations, sales and marketing of commercial products, and development costs for product candidates.
• Potentially seek to retire or purchase outstanding senior convertible notes.
• Comply with the financial covenant of the Blackstone Credit Facility, requiring liquidity of at least $40 million quarterly.

Key Dates

Recommendation

While MannKind's financial performance shows positive trends, including a return to net income and strong royalty growth from Tyvaso DPI, and the new Blackstone credit facility significantly de-risks its liquidity position, the company still faces challenges. V-Go sales are declining, and operating expenses are increasing due to R&D and commercialization efforts. The pipeline, while promising, is still in early to mid-stages, carrying inherent development risks. The stock price remains volatile. A 'hold' recommendation reflects the improved financial stability and positive momentum, balanced against ongoing operational challenges and the long-term risks associated with drug development and market competition.

Keywords

Biopharmaceutical, Orphan Lung Disease, Diabetes, Tyvaso DPI, Afrezza, V-Go, Clinical Trials, FDA Approval, SEC Filing, Financial Results, Liquidity, Debt Financing, Blackstone, MNKD-101, MNKD-201, Royalty Revenue, Corporate Governance, Risk Management